Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC)
PHASE2
Urothelial carcinoma (UC) is the ninth most common cancer type worldwide. W...
A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)
PHASE2
Hepatocellular carcinoma (HCC) is a common cancer worldwide and a leading c...
Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)
PHASE2
Hepatocellular carcinoma (HCC) is a common cancer worldwide and a leading c...
Status
Active Not Recruiting
Location
Arizona Oncology Associates, PC - NAHOA Prescott Valley /ID# 254313
A Study to Assess the Adverse Events and How Intravenously Infused Livmoniplimab in Combination With Budigalimab Moves Through the Bodies of Adult Chinese Participants With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC)
PHASE1
Hepatocellular carcinoma (HCC) is a common cancer worldwide and a leading c...
Status
Active Not Recruiting
Location
Beijing Youan Hospital, Capital Medical University -No differernce with previous /ID# 261928
Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors
PHASE1
The study will determine the recommended Phase 2 dose (RP2D) of livmoniplim...
Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
PHASE2
Non-Squamous Non-Small Cell Lung Cancer (NSCLC) remains a leading cause of ...
Status
Recruiting
Location
UC San Diego Health - Moores Cancer Center /ID# 267782